Yes, getting the drug into the right cell or tissue is still largely unsolved (kidney is easier than brain, of course). But the investors we talk with have drop

Yes, getting the drug into the right cell or tissue is still largely unsolved (kidney is easier than brain, of course). But the investors we talk with have dropped all interest in gene editing, too risky. RNA-based technologies are great, though - ASOs, siRNAs etc. Investors are very happy with those :)